CRANFORD, N.J., Feb. 26, 2020 /PRNewswire/ -- Citius
Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a
specialty pharmaceutical company focused on adjunctive cancer care
and critical care drug products, announced today that the Company
will present at the Third Annual LD Micro Virtual Conference on
Wednesday, March 4, 2020 at
11 AM ET.
Event: Third Annual LD
Micro Virtual Conference
Presentation Date:
Wednesday, March 4, 2020
Presentation Time:
11:00 AM ET
Webcast Link:
https://www.webcaster4.com/Webcast/Page/2019/33349
Chief Executive Officer Myron
Holubiak will deliver an update on the Company, including a
discussion of the recent positive outcome of its interim futility
analysis for the Phase 3 Mino-Lok® pivotal trial, provide an
overview of its other pipeline products, Mino-Wrap™ and Halo-Lido,
and answer questions from investors.
The conference will be held via webcast and will feature over 40
companies in the small / micro-cap space.
About Citius Pharmaceuticals, Inc.
Citius is a
specialty pharmaceutical company dedicated to the development and
commercialization of critical care products, with a focus on
anti-infectives, cancer care, and unique prescription products that
use innovative, patented, or proprietary formulations of
previously-approved active pharmaceutical ingredients. We seek to
achieve leading market positions by providing therapeutic products
that address unmet medical needs. By using previously
approved drugs with substantial safety and efficacy data, we seek
to reduce the risks associated with pharmaceutical product
development and regulatory requirements. Citius develops products
that have intellectual property protection and competitive
advantages to existing therapeutic approaches. For more
information, please visit www.citiuspharma.com.
About LD Micro
LD Micro was founded in 2006 with the
sole purpose of being an independent resource in the microcap
space. What started out as a newsletter highlighting unique
companies has transformed into an event platform hosting several
influential conferences annually (Invitational, Summit, and Main
Event).
In 2015, LDM launched the first pure microcap index (the LDMi)
to exclusively provide intraday information on the entire sector.
LD will continue to provide valuable tools for the benefit of
everyone in the small and microcap universe.
Please see www.ldmicro.com for more information.
Safe Harbor
This press release may contain
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such statements are made based on our
expectations and beliefs concerning future events impacting Citius.
You can identify these statements by the fact that they use words
such as "will," "anticipate," "estimate," "expect," "should," and
"may" and other words and terms of similar meaning or use of future
dates. Forward-looking statements are based on management's current
expectations and are subject to risks and uncertainties that could
negatively affect our business, operating results, financial
condition and stock price. Factors that could cause actual
results to differ materially from those currently anticipated are:
risks associated with conducting our Phase 3 trial for Mino-Lok,
including completing patient enrollment, opening study sites and
achieving the required number of catheter failure events; the
estimated markets for our product candidates and the acceptance
thereof by any market; our need for substantial additional funds;
risks associated with developing Mino-Wrap, including that
preclinical results may not be predictive of clinical results and
our ability to file an IND; risks related to our growth strategy;
our ability to identify, acquire, close and integrate product
candidates and companies successfully and on a timely basis; risks
relating to the results of research and development activities;
uncertainties relating to preclinical and clinical testing; the
early stage of products under development; our ability to obtain,
perform under and maintain financing and strategic agreements and
relationships; our ability to attract, integrate, and retain key
personnel; government regulation; patent and intellectual property
matters; competition; as well as other risks described in our SEC
filings. We expressly disclaim any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our
expectations or any changes in events, conditions or circumstances
on which any such statement is based, except as required by
law.
Contact:
Andrew
Scott
Vice President, Corporate Development
(O) 908-967-6677 x105
ascott@citiuspharma.com
View original
content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-the-2020-ld-micro-virtual-conference-301011218.html
SOURCE Citius Pharmaceuticals, Inc.